Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bioventus Inc. (BVS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered summaries to help interpret key points. As a Nasdaq Global Select Market issuer of Class A common stock, Bioventus files current reports on Form 8-K and other periodic reports that provide insight into its operations, governance and capital structure.
In its Form 8-K filings, Bioventus reports material events such as quarterly and year-to-date financial results, including net sales by business (Pain Treatments, Surgical Solutions and Restorative Therapies), net income and the use of non-GAAP measures like Adjusted EBITDA and non-GAAP earnings. These filings often reference accompanying press releases furnished as exhibits, which our AI tools can summarize to highlight segment performance and notable drivers.
Bioventus also uses Form 8-K to disclose financing arrangements, such as the 2025 Credit Agreement that established a $300 million term loan facility and a $100 million revolving credit facility. The filing details interest rate terms, leverage and coverage covenants, maturity dates and the use of proceeds to refinance prior credit facilities. AI analysis can help readers quickly understand how such agreements affect liquidity, leverage and future obligations.
Additional 8-K items cover governance changes, including the appointment of new directors under the terms of a Stockholders Agreement with certain major stockholders. These disclosures explain board composition, designation rights and whether directors receive compensation from the company.
On this page, users can access Bioventus 10-K annual reports, 10-Q quarterly reports, 8-K current reports and Form 4 insider transaction filings as they become available from EDGAR. Real-time updates and AI-generated explanations are designed to make complex filings more accessible, whether you are reviewing segment disclosures, credit facility terms or board changes related to BVS.
Bioventus Inc. (BVS) filed a Form 8-K to report that on 30 Jul 2025 the U.S. FDA granted 510(k) clearance for two Peripheral Nerve Stimulation (PNS) devices, TalisMann™ and StimTrial™. The decision permits immediate U.S. marketing without additional clinical trials, expanding Bioventus’ portfolio beyond orthobiologics and bone-healing systems.
No revenue, margin or guidance figures were disclosed, yet management signals a new addressable market in neuromodulation. Clearance could diversify revenue streams and leverage the company’s existing sales infrastructure; however, launch timing, pricing, reimbursement and market-share expectations remain unspecified.
- Item reported: 8.01 – Other Events
- Regulatory milestone: FDA 510(k) clearance
- Products affected: TalisMann & StimTrial PNS devices
- Potential impact: accelerates entry into U.S. PNS market, incremental growth driver